Abstract
Surface modified activated carbon with methanesulfonic acid (AC-MsOH) is found to catalyze [3+2] cycloaddition reactions between alkyl/aryl azides and nitroolefins which yielded regioselective 1,5-disubstituted-1,2,3-triazolines in high yields under mild conditions.
Keywords: Activated Carbon, [3+2] Cyclo-addition, 1, 2, 3-triazolines, nitroolefins.
Graphical Abstract
Current Organic Synthesis
Title:Specific Synthesis of 1,5-Disubstituted-1,2,3-triazolines Catalyzed by Surface Modified Activated Carbon with MsOH
Volume: 13 Issue: 1
Author(s): Nanjundaswamy Marishetty Hemmaragala and Heidi Abrahamse
Affiliation:
Keywords: Activated Carbon, [3+2] Cyclo-addition, 1, 2, 3-triazolines, nitroolefins.
Abstract: Surface modified activated carbon with methanesulfonic acid (AC-MsOH) is found to catalyze [3+2] cycloaddition reactions between alkyl/aryl azides and nitroolefins which yielded regioselective 1,5-disubstituted-1,2,3-triazolines in high yields under mild conditions.
Export Options
About this article
Cite this article as:
Marishetty Hemmaragala Nanjundaswamy and Abrahamse Heidi, Specific Synthesis of 1,5-Disubstituted-1,2,3-triazolines Catalyzed by Surface Modified Activated Carbon with MsOH, Current Organic Synthesis 2016; 13 (1) . https://dx.doi.org/10.2174/1570179412666150505184249
DOI https://dx.doi.org/10.2174/1570179412666150505184249 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE
Current Pharmaceutical Design Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Atopic Dermatitis and Cytokines: Recent Patents in Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part I: Cytokines in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design The Role of Leukocytes from L-PRP/L-PRF in Wound Healing and Immune Defense: New Perspectives
Current Pharmaceutical Biotechnology Vitamin D and the Adaptive Immune System with Special Emphasis to Allergic Reactions and Allograft Rejection
Inflammation & Allergy - Drug Targets (Discontinued) New Insights on the Antitumoral Properties of Prodiginines
Current Medicinal Chemistry From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms
Current Pharmaceutical Biotechnology Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Recent Advances in Understanding of Kinetic Interplay Between Phase II Metabolism and Efflux Transport
Current Drug Metabolism